Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
22
02
2019
accepted:
03
06
2019
entrez:
10
9
2019
pubmed:
10
9
2019
medline:
10
9
2019
Statut:
epublish
Résumé
With the success of hepatitis C virus (HCV) direct-acting antiviral therapies, there has been a shift in research focus to the other major chronic liver diseases (CLDs). The use of social media, specifically Twitter, has become a popular platform for understanding public health trends and for performing health care research. To evaluate this, we studied the areas of public interest and social media trends of the following three major CLDs: hepatitis B virus (HBV), HCV, and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). Twitter activity data from January 1, 2013, through January 1, 2019, for HBV, HCV, and NAFLD/NASH were collected using the social media analytic tool Symplur Signals (Symplur LLC) software. Content and regression analyses were performed to understand and predict Twitter activity for each of the CLDs. Over the study period, there were 810,980 tweets generating 4,452,939,516 impressions. HCV tweet activity peaked in 2015 at 243,261 tweets, followed by a decline of 52.4% from 2015 to 2016 with a subsequent plateau through 2018. Meanwhile, NAFLD/NASH and HBV tweet activity has continued to increase, with projections that these two CLDs will surpass HCV by the second half of 2023 and 2024, respectively. Treatment and Management was the most popular content category for HCV and NAFLD/NASH, while Prevention was the most popular content category for HBV.
Identifiants
pubmed: 31497747
doi: 10.1002/hep4.1394
pii: HEP41394
pmc: PMC6719740
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1271-1280Références
J Infect Dis. 2010 Jul 15;202(2):192-201
pubmed: 20533878
J Hepatol. 2012;56 Suppl 1:S88-100
pubmed: 22300469
BJU Int. 2014 Jun;113(6):993-8
pubmed: 24274744
J Pharmacol Pharmacother. 2014 Oct;5(4):278-84
pubmed: 25422576
Int J Mol Cell Med. 2014 Fall;3(4):207-15
pubmed: 25635247
P T. 2015 Apr;40(4):256-76
pubmed: 25859119
Cold Spring Harb Perspect Med. 2015 May 01;5(5):a021410
pubmed: 25934461
Am J Med. 2015 Dec;128(12):1335-50
pubmed: 26159633
P T. 2015 Oct;40(10):649-89
pubmed: 26535020
J Allergy Clin Immunol Pract. 2016 Mar-Apr;4(2):345-6.e1
pubmed: 26626064
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):142-7
pubmed: 26629280
Liver Int. 2016 Dec;36(12):1755-1764
pubmed: 27634134
J Biomed Inform. 2016 Oct;63:390-399
pubmed: 27645323
Am J Public Health. 2017 Jan;107(1):e1-e8
pubmed: 27854532
Liver Int. 2017 Jan;37 Suppl 1:97-103
pubmed: 28052626
Gastroenterology. 2017 Apr;152(5):1090-1099.e1
pubmed: 28088461
JAMA Cardiol. 2017 Jul 1;2(7):820
pubmed: 28329126
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Hepatology. 2017 Oct;66(4):1296-1313
pubmed: 28762522
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
PLoS One. 2017 Aug 23;12(8):e0183031
pubmed: 28832603
Hepatology. 2019 Aug;70(2):487-495
pubmed: 28833326
Br J Surg. 2017 Oct;104(11):1470-1476
pubmed: 28881004
J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):310-312
pubmed: 28939139
Pharmacol Ther. 2018 Mar;183:118-126
pubmed: 29024739
Infect Dis Ther. 2017 Dec;6(4):461-476
pubmed: 29071665
Curr Hematol Malig Rep. 2017 Dec;12(6):598-604
pubmed: 29105027
Semin Hematol. 2017 Oct;54(4):198-204
pubmed: 29153081
Drug Des Devel Ther. 2017 Nov 06;11:3197-3204
pubmed: 29158666
Clin Gastroenterol Hepatol. 2018 Aug;16(8):1356-1358
pubmed: 29199144
Am J Public Health. 2018 Feb;108(2):175-181
pubmed: 29267061
Hepatology. 2018 Jul;68(1):4-6
pubmed: 29655183
J Neurointerv Surg. 2018 Dec;10(12):e33
pubmed: 29678887
Am J Gastroenterol. 2018 Nov;113(11):1649-1659
pubmed: 29880964
Gastroenterology. 2018 Oct;155(4):1154-1163.e3
pubmed: 30009816